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Background: Microcystic adenoma or serous cystadenoma (SCA) is an uncommon tumor type, accounting
for only 1–2% of pancreatic exocrine neoplasms. Usually unifocal, SCAs present as single, large, well-demarcated,
multiloculated, cystic tumors, 1–25 cm in size.
Case presentation: A 73-year-old man initially presented with epigastric abdominal pain and was diagnosed
with SCA involving the whole pancreas. Eleven months later, he presented with obstructive jaundice, and total
pancreatectomy was performed. The removed tissue allowed histological verification of pancreatic SCA.
Histopathological examination showed both microcysts and macrocysts, lined by cuboidal epithelium, with
optically clear cytoplasm and the absence of detectable mitosis or necrosis.
Conclusions: Thus, although relatively rare, pancreatic SCA is one of the differential diagnoses of epigastric
abdominal pain; we recommend early surgical intervention for symptomatic pancreatic SCA.
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Microcystic adenoma or serous cystadenoma (SCA) of the
pancreas is an uncommon, benign tumor that accounts
for 1–2% of pancreatic exocrine neoplasms and 25% of
cystic neoplasms [1]. Their prevalence is increasing,
primarily due to imaging technique improvements. These
tumors are usually unifocal, mostly arising in the body
and tail of the pancreas and are often incidentally
detected. They present as single, large, well demarcated,
and multiloculated cystic tumors, 1–25 cm in size. They
are composed of cysts lined by epithelial cells that produce
serous fluid and show ultrastructural evidence of centroa-
cinar differentiation [2].
The World Health Organization (WHO) has subclassified
these tumors into two groups, serous microcystic adenomas
and serous oligocystic adenomas. The serous microcystic* Correspondence: Jiffrybilal@hotmail.com
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unless otherwise stated.adenoma is a well-demarcated tumor composed of numer-
ous small cysts arranged around a central stellate scar. The
central stellate scar is a dense fibrous core within the tumor,
which may be calcified and from which fibrous trabeculae
radiate to the periphery. The serous oligocystic adenoma is
an often ill-demarcated tumor composed of a few cysts with
diameters of 1–2 cm. Serous cystic tumors showing larger
cysts have been referred to as serous macrocystic adenomas
[3]. A third type, the disseminated variant (DV), has been
recognized because of its rare involvement of the entire
pancreas. In the DV, both of the previously described types
are spread throughout the pancreas. Although DVs are rare,
they are more commonly reported in association with Von
Hippel-Lindau (VHL) disease [4]. VHL disease, which is an
autosomal dominant condition having variable penetrance,
is characterized by central nervous system (CNS) and
retinal hemangioblastomas, visceral cysts, pheochromo-
cytomas, and renal cell carcinoma; pancreatic lesions
are seen in approximately 56% of VHL patients [4]. Cri-
teria for the diagnosis of VHL include the presence of aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Contrast enhanced computed tomography showing
multiple, variably sized cystic lesions with multiple calcific foci
involving the whole pancreas.
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type lesion in an individual or one VHL-type lesion in a
family member if another family member has a CNS
hemangioblastoma [4].
Here, we present a rare case of a pancreatic SCA in-
volving the whole pancreas (DV) that caused obstructive
jaundice, with no association with VHL.
Case presentation
A 73-year-old man, with a history of diabetes mellitus and
hypertension, was referred to our clinic in November 2010
with a 3-year history of epigastric pain that was increasing
in severity. The pain was non-colicky and was not associ-
ated with jaundice or weight loss. The patient did not have
any significant personal or family history with no previous
admissions and had not been previously admitted for in-
vestigation of these symptoms. General and systemicFigure 2 Magnetic resonance cholangiopancreatography showing nu
the pancreatic duct.examinations were normal and his serum biochemistry, in-
cluding liver function tests, amylase and lipase tests were
within normal limits, except for his carbohydrate antigen
(CA 19–9), which was 60 U/mL (normal range 0–10 U/
ml). Abdominal computed tomography (CT) (Figure 1)
showed multiple, variably sized cystic lesions with multiple
calcific foci involving the whole pancreas (Figure 1).
Magnetic resonance imaging (MRI) and magnetic reson-
ance cholangiopancreatography (MRCP) showed numerous
pancreatic cysts involving the entire pancreas, obscuring
the pancreatic duct (Figure 2). A diagnosis of diffuse SCA
was made and he was offered surgical intervention; he
declined and sought a second opinion.
Approximately 1 year later, he presented with obstructive
jaundice and abnormal serum biochemistry results: alkaline
phosphatase, 218 U/L (normal range, 30–120 U/L); total
bilirubin, 82.2 μmol/L (normal range, 0–20 μmol/L); direct
bilirubin, 51.2 μmol/L (normal range 0–15 μmol/L) ; aspar-
tate aminotransferase (AST), 177 U/L (normal range, 0–45
U/L); alanine aminotransferase (ALT), 260 U/L (normal
range, 0–45 U/L); serum amylase, 37 U/L (normal range,
30–110 U/L); serum lipase, 11 U/L (normal range, 5–208
U/L), and CA 19–9, 60 U/mL (normal range, 0–37 U/mL).
Abdominal ultrasonography showed multiple pancre-
atic cysts and a dilated biliary system with common bile
duct (CBD) stones (Figure 3). Endoscopic retrograde
cholangiopancreatography (ERCP) also showed severe
distal CBD narrowing, and the stones were extracted.
Another abdominal CT was done because of the
elapsed time of one year with no follow up. It showed
the absence of any malignant changes and an increase
in the size of some cysts. VHL disease was excluded,
based on a normal neurological examination, normal
visual acuity, and the absence of other organ involve-
ment, including a normal CT brain. Again, the patient
was offered surgical treatment, but he asked formerous pancreatic cysts involving the entire pancreas, obscuring
Figure 3 Abdominal ultrasonography showing multiple pancreatic cysts and a dilated biliary system with common bile duct stones.
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charged without jaundice and in a normal condition.
Two months later, he presented again with obstructive
jaundice. MRI and MRCP were repeated to evaluate the
CBD and demonstrated dilatation of the intrahepatic
and extrahepatic biliary systems, but no stones. The pa-
tient agreed to surgery and underwent total pancreatec-
tomy. Intraoperatively, the entire pancreas (including the
uncinate process) was distorted and replaced by variably
sized cysts, up to 3 cm (Figure 4). Remarkably, the oper-
ation was uneventful without evidence of other organ or
lymph node involvement. The patient’s postoperative
course was uneventful and he was discharged 10 days
later. The patient is currently taking pancreatic enzyme
replacements, and is alive and well 20 months after
surgery.
A microscopic examination (Figure 5) of the pancreatic
specimen showed microcysts and macrocysts lined by
cuboidal epithelium, with optically clear cytoplasm and
the absence of evident mitosis or necrosis.Figure 4 Total pancreatectomy specimen showing diffuse replacemenDiscussion
SCAs are benign cystic tumors composed of cuboidal
epithelium and producing serous fluid [3]. Although rare
cases of serous cyst adenocarcinoma have been reported
[5], the WHO reported that the prevalence of malignant
pancreatic SCAs is 1–3% [5]. This malignant variant is
defined by the presence of metastases in extrapancreatic
organs or tissues [5]. In addition, the presence of invasion
to the adjacent organs is considered a characteristic of ma-
lignancy [6]. SCAs predominate in females in their sixth
decade of life [7] and are asymptomatic in 33% of cases
[7]. Symptoms are frequently non-specific, with abdom-
inal pain being the most common, occurring in 50–60% of
all cases [7]. The tumors rarely cause obstructive jaundice
[6,8-12] and are usually unifocal, situated in the body and
tail of the pancreas, and are multiloculated and cystic in
appearance. The present case can be classified as one of a
multicentric serous tumor involving the entire pancreas
with almost complete obliteration of pancreatic acini and
ducts.t of the pancreas with multiple cysts.
Figure 5 Microscopic examination of the pancreatic specimen a) showing the presence of microcysts and macrocysts, b) The wall lined
by cuboidal epithelium and possessing optically clear cytoplasm without any evidence of mitosis or necrosis.
Al-Jiffry et al. BMC Research Notes 2014, 7:749 Page 4 of 6
http://www.biomedcentral.com/1756-0500/7/749DV pancreatic lesions have been reported in up to 56%
of patients with VHL disease [4], which is an autosomal
dominant genetic disorder. The VHL tumor suppressor
gene, linked to chromosome 3p 2 s, has been identified.
When both copies of this gene are inactivated, there is
unchecked cell growth resulting in tumors and cysts in
the pancreas, kidney, and epididymis. Pancreatic manifes-
tations of VHL are frequently asymptomatic and consist
of SCA or multiple serous cysts, sometimes replacing the
entire pancreas [4]. Reports of SCA, without a family
history of VHL, have also been cited, in part probably due
to sporadic inactivation of the gene [4]. An extensive
review of the literature revealed only 16 reported cases of
SCA associated with obstructive jaundice (including 1 DV
case) [7-12]; 9 were in women and 7 in men, with a mean
age of 59.5 years. However, only 9 cases of DV involving
the entire pancreas have been reported in literature pub-





























NA, not available; A & W, alive and well.best of our knowledge, this is only the second case of DV
pancreatic SCA without VHL causing obstructive jaundice.
The differential diagnosis of SCA from pseudocysts and
other cystic neoplasms is very important because, in
contrast to other cystic neoplasms, SCAs may not require
surgery. Serous microcystic adenomas can be misdiagnosed
as solid lesions if small loculi with septa cannot be visual-
ized [13]. Serous oligocystic adenomas can be misdiagnosed
as either mucinous cystic tumors or pseudocysts because of
their oligocystic or unilocular nature [13]. However, most
patients with pseudocysts have a history of pancreatitis and
they are often older individuals. Hypervascularity is another
feature distinguishing SCA from pseudocysts [14]. Endo-
scopic retrograde pancreatography shows the communica-
tion of the pseudocyst with the pancreatic duct in 70% of
the cases, in contrast to SCAs, which lack such a commu-
nication [13]. On CT scans, mucinous cystic tumors have a
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cysts may have peripheral calcification [14].
Differentiation of SCAs from mucinous cystadenomas
and pseudocysts is usually based on ultrasonography or CT
findings. When the distinction is less clear, fine-needle as-
piration of the cystic lesions for cytology and biochemical
analysis of the fluid may help in establishing the diagnosis.
On cytological analysis, periodic acid-Schiff stains of SCAs
show abundant cytoplasmic glycogen, and stains for mucin
are negative [21]. Cells are cuboidal to polygonal in shape,
without evident mitoses; cytological analysis is diagnostic in
about 20% of cases [22]. Biochemical analysis of cyst fluid
may include tests for amylase and some tumor markers,
such as carcinoembryonic antigen, NB/70K, CA 72–4, CA
125, CA 15–3 tissue polypeptide antigen, and pS2 protein
[23,24]. The amylase content of the fluid in SCAs is usually
lower than the levels in pseudocysts and mucinous cystic
tumors, and SCAs have lower levels of tumor markers
compared with mucinous cystic tumors.
Most authors advise that asymptomatic patients be
closely monitored, so long as potentially malignant cystic
tumors, mainly mucinous cystadenoma or intraductal
papillary mucinous tumor, can be definitively excluded.
Surgical intervention is indicated for patients with symp-
tomatic lesions and those with an uncertain diagnosis
[25,26]. Size of the cyst at presentation is still debatable
since some reports indicate resection for cysts >4 cm
and others do not [27].
Recently published guidelines for cystic pancreatic man-
agement suggest that resection should be considered for all
symptomatic cases of SCA, for patients with cysts >4 cm,
in case of presence of mural nodules, dilatation of main
pancreatic duct >6 mm, increased serum levels of
carbohydrate antigen (CA 19–9), or in case of rapid in-
crease in size [28,29].Conclusions
In conclusion, SCAs of the pancreas are increasing in
frequency of diagnosis because of advances in imaging
techniques. The differentiation of SCAs from other cystic
tumors, as well as from non-neoplastic cysts, is very
important because of the great differences in the manage-
ment of these different entities. This case highlights an
extremely rare case of SCA involving the whole pancreas
(DV) causing obstructive jaundice, without an association
with VHL disease.Consent
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